PL366792A1 - Pochodne 4-(benzylidenoamino)-3-(metylosulfanylo)-4H-1,2,4-triazyno-5-onu o działaniu inhibitującymPDE IV i antagonistycznym do TNF do terapii chorób serca i alergii - Google Patents
Pochodne 4-(benzylidenoamino)-3-(metylosulfanylo)-4H-1,2,4-triazyno-5-onu o działaniu inhibitującymPDE IV i antagonistycznym do TNF do terapii chorób serca i alergiiInfo
- Publication number
- PL366792A1 PL366792A1 PL02366792A PL36679202A PL366792A1 PL 366792 A1 PL366792 A1 PL 366792A1 PL 02366792 A PL02366792 A PL 02366792A PL 36679202 A PL36679202 A PL 36679202A PL 366792 A1 PL366792 A1 PL 366792A1
- Authority
- PL
- Poland
- Prior art keywords
- inhibiting
- treatment
- diseases
- derivatives
- methylsulfanyl
- Prior art date
Links
- 230000002401 inhibitory effect Effects 0.000 title abstract 2
- DWDLWOKBQDXJDK-UHFFFAOYSA-N 4-(benzylideneamino)-3-methylsulfanyl-1,2,4-triazin-5-one Chemical class CSC1=NN=CC(=O)N1N=CC1=CC=CC=C1 DWDLWOKBQDXJDK-UHFFFAOYSA-N 0.000 title 1
- 206010020751 Hypersensitivity Diseases 0.000 title 1
- 230000007815 allergy Effects 0.000 title 1
- 230000000694 effects Effects 0.000 title 1
- 208000019622 heart disease Diseases 0.000 title 1
- 208000030507 AIDS Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010006458 Bronchitis chronic Diseases 0.000 abstract 1
- 206010006895 Cachexia Diseases 0.000 abstract 1
- 206010009900 Colitis ulcerative Diseases 0.000 abstract 1
- 208000011231 Crohn disease Diseases 0.000 abstract 1
- 206010012438 Dermatitis atopic Diseases 0.000 abstract 1
- 208000026139 Memory disease Diseases 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 206010040047 Sepsis Diseases 0.000 abstract 1
- 206010052779 Transplant rejections Diseases 0.000 abstract 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract 1
- 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 abstract 1
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 abstract 1
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 201000008937 atopic dermatitis Diseases 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 206010006451 bronchitis Diseases 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 abstract 1
- 208000007451 chronic bronchitis Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000017520 skin disease Diseases 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 150000003918 triazines Chemical class 0.000 abstract 1
- 230000004614 tumor growth Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/06—1,2,4-Triazines
- C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
- C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D253/075—Two hetero atoms, in positions 3 and 5
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Transplantation (AREA)
- Psychiatry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2001135009 DE10135009A1 (de) | 2001-07-18 | 2001-07-18 | Triazinderivate |
| DE2001156229 DE10156229A1 (de) | 2001-11-15 | 2001-11-15 | Triazinderivate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL366792A1 true PL366792A1 (pl) | 2005-02-07 |
Family
ID=26009725
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL02366792A PL366792A1 (pl) | 2001-07-18 | 2002-06-19 | Pochodne 4-(benzylidenoamino)-3-(metylosulfanylo)-4H-1,2,4-triazyno-5-onu o działaniu inhibitującymPDE IV i antagonistycznym do TNF do terapii chorób serca i alergii |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7485639B2 (pl) |
| EP (1) | EP1406878B1 (pl) |
| JP (1) | JP4546082B2 (pl) |
| KR (1) | KR20040023655A (pl) |
| CN (1) | CN1531529A (pl) |
| AT (1) | ATE328875T1 (pl) |
| AU (1) | AU2002354850B2 (pl) |
| BR (1) | BR0211209A (pl) |
| CA (1) | CA2453974C (pl) |
| CZ (1) | CZ2004213A3 (pl) |
| DE (1) | DE50207119D1 (pl) |
| ES (1) | ES2266539T3 (pl) |
| HU (1) | HUP0401115A3 (pl) |
| MX (1) | MXPA04000538A (pl) |
| PL (1) | PL366792A1 (pl) |
| RU (1) | RU2004104945A (pl) |
| SK (1) | SK942004A3 (pl) |
| WO (1) | WO2003008392A1 (pl) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090105314A1 (en) * | 2006-05-15 | 2009-04-23 | Takeda Pharmaceutical Company Limited | Pharmaceutical Agent |
| JP5775299B2 (ja) * | 2007-04-10 | 2015-09-09 | アンセルム（アンスチチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル） | 血管障害治療のためのｍｒｐ４阻害剤 |
| EA201591360A1 (ru) | 2013-02-19 | 2016-03-31 | Пфайзер Инк. | Азабензимидазолы в качестве ингибиторов изозимов фдэ4 для лечения цнс и других расстройств |
| JP6713982B2 (ja) | 2014-07-24 | 2020-06-24 | ファイザー・インク | ピラゾロピリミジン化合物 |
| AP2017009744A0 (en) | 2014-08-06 | 2017-02-28 | Pfizer | Imidazopyridazine compounds |
| CN104997766A (zh) * | 2015-08-22 | 2015-10-28 | 南京华宽信息咨询中心 | 一种治疗或预防慢性心衰药物及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4036632A (en) * | 1966-04-16 | 1977-07-19 | Bayer Aktiengesellschaft | Herbicidal agents |
| CH495110A (de) * | 1966-04-16 | 1970-08-31 | Bayer Ag | Herbizides Mittel |
| US4346220A (en) * | 1966-11-28 | 1982-08-24 | E. I. Du Pont De Nemours And Company | 1,2,4-Triazin-5-ones |
| US3905801A (en) * | 1966-11-28 | 1975-09-16 | Du Pont | Substituted 1,2,4-triazine-5-ones as herbicides |
| US4345220A (en) * | 1980-02-12 | 1982-08-17 | The United States Of America As Represented By The Secretary Of The Air Force | High power microwave generator using relativistic electron beam in waveguide drift tube |
| JPS61134389A (ja) * | 1984-12-04 | 1986-06-21 | Shionogi & Co Ltd | トリアジノン誘導体および抗潰瘍剤 |
| DE19533975A1 (de) | 1995-09-14 | 1997-03-20 | Merck Patent Gmbh | Arylalkyl-diazinone |
| EP0927171B1 (en) | 1996-09-16 | 2002-02-20 | Du Pont Pharmaceuticals Company | Pyrazinones and triazinones and their derivatives thereof |
| US6290929B1 (en) * | 2000-07-28 | 2001-09-18 | The Procter & Gamble Company | Cancer treatment |
-
2002
- 2002-06-19 AT AT02751042T patent/ATE328875T1/de not_active IP Right Cessation
- 2002-06-19 AU AU2002354850A patent/AU2002354850B2/en not_active Ceased
- 2002-06-19 RU RU2004104945/04A patent/RU2004104945A/ru not_active Application Discontinuation
- 2002-06-19 PL PL02366792A patent/PL366792A1/pl unknown
- 2002-06-19 SK SK94-2004A patent/SK942004A3/sk unknown
- 2002-06-19 JP JP2003513952A patent/JP4546082B2/ja not_active Expired - Fee Related
- 2002-06-19 CZ CZ2004213A patent/CZ2004213A3/cs unknown
- 2002-06-19 EP EP02751042A patent/EP1406878B1/de not_active Expired - Lifetime
- 2002-06-19 ES ES02751042T patent/ES2266539T3/es not_active Expired - Lifetime
- 2002-06-19 KR KR10-2004-7000765A patent/KR20040023655A/ko not_active Withdrawn
- 2002-06-19 WO PCT/EP2002/006742 patent/WO2003008392A1/de not_active Ceased
- 2002-06-19 BR BR0211209-4A patent/BR0211209A/pt not_active Application Discontinuation
- 2002-06-19 DE DE50207119T patent/DE50207119D1/de not_active Expired - Lifetime
- 2002-06-19 MX MXPA04000538A patent/MXPA04000538A/es unknown
- 2002-06-19 US US10/484,172 patent/US7485639B2/en not_active Expired - Fee Related
- 2002-06-19 HU HU0401115A patent/HUP0401115A3/hu unknown
- 2002-06-19 CA CA2453974A patent/CA2453974C/en not_active Expired - Fee Related
- 2002-06-19 CN CNA028143566A patent/CN1531529A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ES2266539T3 (es) | 2007-03-01 |
| CA2453974C (en) | 2011-01-11 |
| AU2002354850B2 (en) | 2008-02-28 |
| KR20040023655A (ko) | 2004-03-18 |
| HUP0401115A3 (en) | 2005-11-28 |
| ATE328875T1 (de) | 2006-06-15 |
| CA2453974A1 (en) | 2003-01-30 |
| JP4546082B2 (ja) | 2010-09-15 |
| EP1406878A1 (de) | 2004-04-14 |
| RU2004104945A (ru) | 2005-07-10 |
| SK942004A3 (en) | 2004-06-08 |
| HUP0401115A2 (hu) | 2004-09-28 |
| US7485639B2 (en) | 2009-02-03 |
| CN1531529A (zh) | 2004-09-22 |
| CZ2004213A3 (cs) | 2004-06-16 |
| EP1406878B1 (de) | 2006-06-07 |
| WO2003008392A1 (de) | 2003-01-30 |
| US20040176252A1 (en) | 2004-09-09 |
| MXPA04000538A (es) | 2004-05-04 |
| DE50207119D1 (de) | 2006-07-20 |
| JP2004535468A (ja) | 2004-11-25 |
| BR0211209A (pt) | 2004-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA94437C2 (en) | Heterocyclic janus kinase 3 inhibitors | |
| AU2004236006B2 (en) | Derivatives of piperidinyl- and piperazinyl-alkyl carbamates, preparation methods thereof and application of same in therapeutics | |
| SI1480961T1 (sl) | Inhibitorji dpiv na osnovi glutaminila | |
| WO2006047277A3 (en) | Inhibitors of c-fms kinase | |
| NZ593096A (en) | Carbazole carboxamide compounds useful as kinase inhibitors | |
| MXPA04004263A (es) | Hidrazono-malonitrilos. | |
| NO20021691L (no) | Benzodiazepinderivater | |
| MX2007008784A (es) | Derivados de pirazol para la inhibicion de las cdks y gsks. | |
| BR9911177A (pt) | Arilalcanoilpiridazinas | |
| WO2006070195A8 (en) | Pyrazole compounds that modulate the activity of cdk, gsk and aurora kinases | |
| PT2021335E (pt) | Compostos heterocíclicos como inibidores de c-fms quinase | |
| WO2003022838A8 (en) | Pyridine substituted furan derivatives as raf kinase inhibitors | |
| YU84603A (sh) | Novi inhibitori tirozin kinaze | |
| CA2953989C (en) | Gls1 inhibitors for treating disease | |
| IL160522A (en) | 1h - imidazole derivatives having cb1 agonistic, cb1 partial agonistic or cb1-antagonistic activity | |
| SG159380A1 (en) | Heteroaryl compounds useful as inhibitors of gsk-3 | |
| BR0311343A (pt) | Derivados de piridazina | |
| WO2002022602A3 (en) | Triazole compounds useful as protein kinase inhibitors | |
| RU2004130440A (ru) | Производные 4-(имидазол-5-ил)-2-(4-сульфоанилино)пиримидина, обладающие ингибирующим действием по отношению к cdk | |
| TW200634015A (en) | Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders | |
| US9388165B2 (en) | Isoquinoline-5-carboxamide derivative having inhibitory activity for protein kinase | |
| GEP20033029B (en) | Substituted 1,8-Naphthyridin-4(1H)-Ones as Phosphodiesterase 4 Inhibitors | |
| RU2002113750A (ru) | Производные пиррола в качестве ингибиторов фосфодиэстеразы VII | |
| NO20043900L (no) | Heterocykliske forbindelser som inhiberer leukocyttadhesjon formidlet av integriner | |
| PL366792A1 (pl) | Pochodne 4-(benzylidenoamino)-3-(metylosulfanylo)-4H-1,2,4-triazyno-5-onu o działaniu inhibitującymPDE IV i antagonistycznym do TNF do terapii chorób serca i alergii |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DISC | Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications) |